Analysts to home in on expenses in Genmab's Wednesday fiscal report
Analysts are awaiting Genmab's fiscal report with anticipation, not due to the sales figures for Darzalex and Kesimpta, but because of expenses.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Analysts will be homing in on listed expenses when Genmab publishes its fiscal report for the first three months of the year on Wednesday afternoon after the stock exchange closes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab drug becomes more accessible in the US
For subscribers
